Drug intelligence / Profile preview

ev148

Development stage: Preclinical
Lead developer: Eradivir

Overview

EV148 is an antiviral drug candidate developed by Eradivir for the treatment of respiratory syncytial virus (RSV)[11]. It is built on Eradivir's BAiT (Biological and Immunological Therapeutics) platform, which is a proprietary technology for developing antiviral agents[6]. No information is available regarding specific mechanisms of action, indications, clinical trial status, formulation, or chemical structure. There is no public evidence that EV148 is approved for use or under active clinical investigation as of the latest available data.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on ev148.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ev148.

Explore the full profile